Radiotherapy dose may not affect prognosis in ESCC patients receiving first-line chemoradiotherapy-immunotherapy: A multicenter retrospective study

Key Points

• Higher radiotherapy doses do not improve survival rates in ESCC patients receiving triple therapy, affecting treatment strategies.
• The analysis indicated that higher doses showed no significant survival advantage, signaling a need for clinical reassessment.
• Observational analysis of multicenter data from China revealed consistent outcomes across diverse settings for ESCC treatment.
• This finding highlights possible reevaluation of radiotherapy protocols, indicating that dosage adjustments may be unnecessary in this context.